DaVita Heads Into Q3 Print With Bears on the Back Foot

DVA reports third-quarter results on October 29 with short sellers cautiously positioned and the stock trading near flat on the month, but the shadow of a brutal August sell-off still hangs over the setup.

The lending market tells a calm story heading into the print. Availability is wide at 408%, meaning roughly four shares remain available to borrow for every one already lent out, well above the 52-week trough of 165%. Borrowing costs have eased to 0.46%, down more than 10% over the past week. Short interest at 7.2% of the free float is meaningful but has barely moved this week, and the month-on-month build of around 8% appears to have stalled in recent sessions. Options positioning nudges the picture slightly more defensive: the put/call ratio has edged up to 0.53, about 1.7 standard deviations above its 20-day average of 0.50. That is still far below the 52-week peak of 1.54, so the move looks more like mild caution than outright fear.

The bull-bear debate centres on a structural tension that has defined the stock all year. Bulls point to DaVita's scale, roughly 35% of US dialysis clinic capacity and around 280,000 patients annually, and to the stable Medicare reimbursement backdrop that anchors two-thirds of US revenue. The 57% year-to-date gain reflects confidence that this durable position justifies a re-rating. Bears counter that the business's profit engine runs on the 10% of patients covered by commercial insurers, a mix that is becoming less favourable, while organic volume growth is softening. The consensus sits at hold, with targets ranging from around $215 to $270 after a cluster of post-August analyst moves. TD Cowen upgraded to Buy in August while trimming its target to $220; Truist and Barclays both held their ratings but adjusted targets lower after last quarter's results. With the stock at $183.64, most targets sit comfortably above the current price, but the discount reflects unresolved questions about margin sustainability rather than a distressed setup.

The most consequential fact in the snapshot is what happened last time DaVita reported. The stock fell 19% on the day of the August print and dropped a further 5 percentage points over the following week, a 24% peak-to-trough move in five sessions. That reaction erased roughly three months of gains and prompted the fresh wave of analyst target reductions. The stock has since clawed back to near its pre-earnings level, which in itself speaks to underlying demand, partly explained by Berkshire Hathaway's 45% stake (filed as a Schedule 13D, making Warren Buffett a named activist holder on the register). Berkshire trimmed 183,000 shares in late July at around $199.55, the only meaningful open-market sale in the insider record over the past 90 days. The reduction is notable but leaves Berkshire's position effectively unchanged as a proportion of the company.

Retail attention has picked up sharply, with the Wikipedia pageviews signal running at a z-score of nearly 3.0 against DaVita's own 90-day history, suggesting the stock is drawing more eyeballs than usual ahead of the report. Whether that attention is drawn by the stock's recovery, Berkshire's involvement, or anxiety about another August-style miss, the October 29 print will test whether the structural profit mix concerns that triggered last quarter's sell-off have improved, stabilised, or worsened further.